EUVIMEDEUVIMED entdecken
Crossref

Evaluation of DICER1 Immunohistochemistry as a Potential Surrogate for Mutation Status in Ovarian Sex Cord–Stromal Tumors

Kristýna Němejcová, Nikola Hájková, Michaela Kendall Bártů, Adam Šafanda, Marián Švajdler, Tetiana Shatokhina, Jan Laco, Radoslav Matěj, Jitka Hausnerová, Jozef Škarda, Monika Náležinská, Tomáš Zima und 1 weitere

Modern Pathology · 2026-05 · 39 (5) · 100990

DOI: 10.1016/j.modpat.2026.100990 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026-05. Verfasst von Kristýna Němejcová und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Electronic …. Hauptthemen laut MEDLINE: Ribonuclease III, DEAD-box RNA Helicases, Sex Cord-Gonadal Stromal Tumors, Ovarian Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Univerzita Karlova v Praze, Ministerstvo Zdravotnictví Ceské Republiky, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diagnosing ovarian sex cord-stromal tumors can be difficult in some cases due to the overlapping morphological and immunohistochemical features, especially for adult granulosa cell tumors (AGCTs), juvenile granulosa cell tumors (JGCT), Sertoli-Leydig cell tumors (SLCT), and thecomas. In such situations, molecular testing can be helpful, as these tumors are often associated with specific genetic alterations. SLCTs, for instance, are known to be associated with DICER1 mutations. However, expression of DICER1 has not yet been systematically investigated in sex cord-stromal tumors. We evaluated the potential use of DICER1 immunohistochemistry for detecting DICER1 mutations in ovarian sex cord-stromal tumors, including 267 AGCT, 38 SLCT, 5 JGCT, and 21 Leydig cell tumors/steroid cell tumors (SCT). Specifically, DICER1 positivity was found in 21/38 (55.3%) of SLCTs, and 16/21 (76.2%) SCT. All DICER1-positive moderately differentiated SLCTs harbored DICER1 mutation. One DICER1-negative moderately differentiated SLCT carried two DICER1 mutations. Additionally, 3/10 well differentiated SLCTs showed immunohistochemical positivity. No SCT harbored DICER1 mutation. Among AGCTs, 4/267 (1.5%) were DICER1-positive, one of these cases harbored two DICER1 mutations. No JGCT demonstrated DICER1 mutation or expression. In cases with both analyses available, DICER1 expression was found in 39/273 (14.3%), while 21/273 (7.7%) harbored DICER1 mutation. Using an optimal cut-off of ≥ 10 % positive tumor cells, immunohistochemistry closely matched mutational status (sensitivity of 90.5%, specificity 92.1%). Our study found substantial concordance between DICER1 immunohistochemistry and mutation status in subset of sex cord-stromal tumors, suggesting that immunohistochemical detection of DICER1 protein may serve as a useful surrogate marker of DICER1 mutation, especially in SLCTs and AGCT. This could be particularly valuable in settings where molecular testing is limited by cost and/or availability. However, in SCT the DICER1 expression is common, but unrelated to DICER1 mutation. This suggests that alternative mechanisms, potentially involving androgen-related pathways, may contribute to DICER1 expression in these tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ribonuclease IIIDEAD-box RNA HelicasesSex Cord-Gonadal Stromal TumorsOvarian NeoplasmsImmunohistochemistryBiomarkers, TumorHumansFemaleMutationAdultDNA Mutational AnalysisMiddle AgedSertoli-Leydig Cell TumorYoung AdultAdolescent

Stichwörter der Autor:innen

DICER1immunohistochemistryovarian tumorssex cord–stromal tumor

Substanzen

Ribonuclease IIIDEAD-box RNA HelicasesDICER1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Electronic address: Kristyna.Nemejcova@vfn.cz.
  • Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
  • Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • The Fingerland Department of Pathology, Charles University Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Czech Republic.
  • Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic; Department of Pathology, Charles University, Third Faculty of Medicine, Universit…

Förderung

  • Univerzita Karlova v Praze
  • Ministerstvo Zdravotnictví Ceské Republiky
  • European Regional Development Fund
  • Všeobecná Fakultní Nemocnice v Praze

Zitieren

APA

Němejcová, K., Hájková, N., Kendall Bártů, M., Šafanda, A., Švajdler, M., Shatokhina, T., Laco, J., Matěj, R., Hausnerová, J., Škarda, J., Náležinská, M., Zima, T., & Dundr, P. (2026). Evaluation of DICER1 Immunohistochemistry as a Potential Surrogate for Mutation Status in Ovarian Sex Cord–Stromal Tumors. Modern Pathology, 39(5), 100990. https://doi.org/10.1016/j.modpat.2026.100990

Vancouver

Němejcová K, Hájková N, Kendall Bártů M, Šafanda A, Švajdler M, Shatokhina T, et al. Evaluation of DICER1 Immunohistochemistry as a Potential Surrogate for Mutation Status in Ovarian Sex Cord–Stromal Tumors. Modern Pathology. 2026;39(5):100990. doi:10.1016/j.modpat.2026.100990

BibTeX
@article{Nmejcov2026,
  author = {Němejcová, Kristýna and Hájková, Nikola and Kendall Bártů, Michaela and Šafanda, Adam and Švajdler, Marián and Shatokhina, Tetiana and Laco, Jan and Matěj, Radoslav and Hausnerová, Jitka and Škarda, Jozef and Náležinská, Monika and Zima, Tomáš and Dundr, Pavel},
  title = {Evaluation of DICER1 Immunohistochemistry as a Potential Surrogate for Mutation Status in Ovarian Sex Cord–Stromal Tumors},
  journal = {Modern Pathology},
  year = {2026},
  volume = {39},
  number = {5},
  pages = {100990},
  doi = {10.1016/j.modpat.2026.100990}
}
Kostenlos starten →